Faecal calprotectin in children with clinically quiescent inflammatory bowel disease

Scandinavian Journal of Gastroenterology

Volumn 45, Issue 7-8, 2010, Pages 872-877

  Sipponen, Taina ^a   Kolho, Kaija Leena ^b  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Crohn's disease; Faecal markers; Paediatric IBD; Ulcerative colitis

Indexed keywords

AZATHIOPRINE; CALGRANULIN; MESALAZINE;

ADOLESCENT; ARTICLE; CHILD; CROHN DISEASE; CROSS-SECTIONAL STUDY; DISEASE EXACERBATION; ENTERITIS; FECES ANALYSIS; FEMALE; FOLLOW UP; HUMAN; ILEOCOLITIS; ILEUM CROHN DISEASE; INDETERMINATE COLITIS; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PREDICTION AND FORECASTING; PRESCHOOL CHILD; PRIORITY JOURNAL; RELAPSE; REMISSION; SCHOOL CHILD; ULCERATIVE COLITIS;

ADOLESCENT; BIOLOGICAL MARKERS; CHILD; FECES; FEMALE; HUMANS; INFLAMMATORY BOWEL DISEASES; LEUKOCYTE L1 ANTIGEN COMPLEX; MALE; SEVERITY OF ILLNESS INDEX;

EID: 77955701075     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.3109/00365521003782389     Document Type: Article

References (23)

1. Roseth AG, Fagerhol MK, Aadland E, Schjonsby H. Assessment of the neutrophil dominating protein calprotectin in feces. A methodologic study. Scand J Gastroenterol 1992;27:793-798
2. Bunn SK, Bisset WM, Main MJ, Golden BE. Fecal calprotectin as a measure of disease activity in childhood inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2001;32:171-177
3. Bunn SK, Bisset WM, Main MJ, Gray ES, Olson S, Golden BE. Fecal calprotectin: validation as a noninvasive measure of bowel inflammation in childhood inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2001;33: 14-22.
4. Fagerberg UL, Lööf L, Lindholm J, Hansson LO, Finkel Y. Fecal calprotectin: a quantitative marker of colonic inflammation in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2007;45:414-420
5. Walker TR, Land ML, Kartashov A, Saslowsky TM, Lyerly DM, Boone JH, et al. Fecal lactoferrin is a sensitive and specific marker of disease activity in children and young adults with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2007;44:414-422
6. Gisbert JP, McNicholl AG. Questions and answers on the role of faecal calprotectin as a biological marker in inflammatory bowel disease. Dig Liver Dis 2009;41:56-66.
7. Canani RB, Terrin G, Rapacciuolo L, Miele E, Siani MC, Puzone C, et al. Faecal calprotectin as reliable non-invasive marker to assess the severity of mucosal inflammation in children with inflammatory bowel disease. Dig Liver Dis 2008;40:547-553
8. Quail MA,Russell RK, Van Limbergen JE, Rogers P, Drummond HE, Wilson DC, et al. Fecal calprotectin complements routine laboratory investigations in diagnosing childhood inflammatory bowel disease. Inflamm Bowel Dis 2009;15:756-759
9. Langhorst J, Elsenbruch S, Koelzer J, Rueffer A,Michalsen A, Dobos GJ. Noninvasivemarkers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices. Am J Gastroenterol 2008;103:162-169
10. Diamanti A, Colistro F, Basso MS, Papadatou B, Francalanci P, Bracci F, et al. Clinical role of calprotectin assay in determining histological relapses in children affected by inflammatory bowel diseases. Inflamm Bowel Dis 2008;14:1229-1235
11. Kolho KL, Raivio T, Lindahl H, Savilahti E. Fecal calprotectin remains high during glucocorticoid therapy in children with inflammatory bowel disease. Scand J Gastroenterol 2006;41:720-725
12. Sipponen T, Savilahti E, Kärkkäinen P, Kolho KL, Nuutinen H, Turunen U, et al. Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti-TNF-alpha therapy for Crohn's disease. Inflamm Bowel Dis 2008;14:1392-1398
13. Sipponen T, af Björkesten C-G, Färkkilä M, Nuutinen H, Savilahti E, Kolho K-L. Faecal calprotectin and lactoferrin are reliable surrogate markers of endoscopic response during Crohn's disease treatment. Scand J Gastroenterol 2009; Epub ahead of print.
14. Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterol Suppl 1989;170:2-6.
15. Berni Canani R, Rapacciuolo L, Romano MT, Tanturri de Horatio L, Terrin G, Manguso F, et al. Diagnostic value of faecal calprotectin in paediatric gastroenterology clinical practice. Dig Liver Dis 2004;36:467-470
16. Tibble JA, Sigthorsson G, Bridger S, Fagerhol MK, Bjarnason I. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology 2000;119:15-22.
17. Walkiewicz D, Werlin SL, Fish D, Scanion M, Hanaway P, Kugathasan S. Fecal calprotectin is useful in predicting disease relapse in pediatric inflammatory bowel disease. Inflamm Bowel Dis 2008;14:669-673
18. Gisbert JP, Bermejo F, Perez-Calle JL, Taxonera S, Vera I, McNicholl AG, et al. Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse. Inflamm Bowel Dis 2009;15:1190-1198
19. Heyman MB, Kirschner BS, Gold BD, Ferry G, Baldassano R, Cohen SA, et al. Children with early-onset inflammatory bowel disease (IBD): analysis of a pediatric IBD consortium registry. J Pediatr 2005;146:35-40.
20. Sipponen T, Savilahti E, Kolho KL, Nuutinen H, Turunen U, Färkkilä M. Crohn's disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn's disease activity index and endoscopic findings. Inflamm Bowel Dis 2008;14:40-46
21. Baert F, Moortgat L, Van Assche G, Caenepeel P, Vergauwe P, Vos MD, et al. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease. Gastroenterology 2009; Epub ahead of print.
22. Turner D, Griffiths AM, Mack D, Otley AR, Seow CH, Steinhart AH, et al. Assessing disease activity in ulcerative colitis: Patients or their physicians? Inflamm Bowel Dis 2009; Epub ahead of print.
23. Stjernman H, Tysk C, Almer S, Ström M, Hjortswang H. Factors predicting the outcome of disease activity assessment in Crohn's disease. Inflamm Bowel Dis 2009;15:1859-1866